WO2002102345A3 - Deferoxamine comme inhibiteur de no-synthase et utilisations - Google Patents

Deferoxamine comme inhibiteur de no-synthase et utilisations Download PDF

Info

Publication number
WO2002102345A3
WO2002102345A3 PCT/FR2002/002065 FR0202065W WO02102345A3 WO 2002102345 A3 WO2002102345 A3 WO 2002102345A3 FR 0202065 W FR0202065 W FR 0202065W WO 02102345 A3 WO02102345 A3 WO 02102345A3
Authority
WO
WIPO (PCT)
Prior art keywords
deferoxamine
synthase inhibitor
composition
desferal
synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/002065
Other languages
English (en)
Other versions
WO2002102345A2 (fr
Inventor
Marie-Madeleine Cals-Grierson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of WO2002102345A2 publication Critical patent/WO2002102345A2/fr
Publication of WO2002102345A3 publication Critical patent/WO2002102345A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invention a pour objet I'utilisation d'une quantite efficace de Deferoxamine (Desferal) dans un milieu physiologiquement acceptable, dans une composition ou pour la preparation d'une composition, le Desferal ou la composition etant destine a inhiber la NO-synthase.
PCT/FR2002/002065 2001-06-15 2002-06-14 Deferoxamine comme inhibiteur de no-synthase et utilisations Ceased WO2002102345A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/07876 2001-06-15
FR0107876A FR2825920B1 (fr) 2001-06-15 2001-06-15 Desferal comme inhibiteur de no-synthase et utilisations

Publications (2)

Publication Number Publication Date
WO2002102345A2 WO2002102345A2 (fr) 2002-12-27
WO2002102345A3 true WO2002102345A3 (fr) 2003-03-20

Family

ID=8864372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/002065 Ceased WO2002102345A2 (fr) 2001-06-15 2002-06-14 Deferoxamine comme inhibiteur de no-synthase et utilisations

Country Status (2)

Country Link
FR (1) FR2825920B1 (fr)
WO (1) WO2002102345A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
FR2940615B1 (fr) 2008-12-30 2011-12-30 Oreal Association de monosaccharides avec des agents antioxydants et son utilisation en cosmetique
AU2010286054B2 (en) 2009-08-19 2016-10-27 Mordechai Chevion Desferrioxamine-metal complexes for the treatment of immune-related disorders
JP7118591B2 (ja) 2017-02-28 2022-08-16 ロレアル レゾルシノール又はその誘導体を含む組成物
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3852711A4 (fr) * 2018-09-20 2022-06-08 Tautona Group IP Holding Company, L.L.C. Composés de chélation du fer pour traiter des affections cutanées esthétiques
JP7412898B2 (ja) 2019-04-26 2024-01-15 ロレアル 特異な粒子と親油性抗酸化剤との組み合わせ
JP7612326B2 (ja) 2019-12-16 2025-01-14 ロレアル 特定の成分の組合せを含む安定な組成物
KR20240099313A (ko) 2021-12-20 2024-06-28 로레알 레티노이드를 포함하는 안정한 조성물
WO2023120390A1 (fr) 2021-12-20 2023-06-29 L'oreal Composition stable comprenant un rétinoïde et un composé d'acide ascorbique
FR3131845B1 (fr) 2022-01-19 2024-11-01 Oreal Composition stable comprenant un rétinoïde
FR3131837B1 (fr) 2022-01-19 2024-10-04 Oreal Composition stable comprenant un rétinoïde et un composé acide ascorbique
WO2024135424A1 (fr) 2022-12-20 2024-06-27 L'oreal Composition comprenant un complexe polyionique à base d'acide hyaluronique et un antioxydant hydrophile ou lipophile
FR3145279B1 (fr) 2023-01-30 2026-01-30 Oreal Composition comprenant un complexe polyionique à base d’acide hyaluronique et un antioxydant lipophile
FR3145278B1 (fr) 2023-01-30 2026-04-10 Oreal Composition de dispersion stable comprenant un rétinoïde
WO2024135577A1 (fr) 2022-12-23 2024-06-27 L'oreal Composition de dispersion stable comprenant du rétinoïde
FR3148912B1 (fr) 2023-05-24 2026-02-20 Oreal Composition comprenant des polymères cationiques et anioniques
FR3152226B3 (fr) 2023-08-25 2025-09-19 Oreal Composition cosmétique anhydre pour une application douce et peu grasse

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7302M (fr) * 1966-03-04 1969-09-29
EP0313305A2 (fr) * 1987-10-22 1989-04-26 The Procter & Gamble Company Compositions photoprotectrices contenant des agents chélatants
EP0535446A1 (fr) * 1991-09-30 1993-04-07 BONISCONTRO E GAZZONE S.r.l. Compositions pharmaceutiques à usage topique contenant un agent de chelation, un tocophérol et un agent antimicrobien
WO1994026263A2 (fr) * 1993-05-06 1994-11-24 The Wellcome Foundation Limited Utilisation d'un complexe metallique de transition pour le traitement du choc septique
WO1996030012A1 (fr) * 1995-03-24 1996-10-03 Defeudis Francis V Procedes de traitement de conditions associees a des excedents d'oxyde d'azote
JPH08333260A (ja) * 1995-06-06 1996-12-17 Kaminomoto Honpo:Kk 皮膚外用剤
WO1997015280A1 (fr) * 1995-10-26 1997-05-01 L'oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
US5683684A (en) * 1991-04-03 1997-11-04 L'oreal Use of sphingolipids in the preparation of a cosmetic or dermopharmaceutical composition protecting the skin and hair against the harmful effects of atmospheric pollution
JPH10120557A (ja) * 1996-10-16 1998-05-12 Sekisui Chem Co Ltd 創傷治療物質
JPH10279485A (ja) * 1997-04-01 1998-10-20 Nisshin Oil Mills Ltd:The 組成物
US6150405A (en) * 1985-07-18 2000-11-21 Proctor; Peter H. Hair loss treatment with ascorbates

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7302M (fr) * 1966-03-04 1969-09-29
US6150405A (en) * 1985-07-18 2000-11-21 Proctor; Peter H. Hair loss treatment with ascorbates
EP0313305A2 (fr) * 1987-10-22 1989-04-26 The Procter & Gamble Company Compositions photoprotectrices contenant des agents chélatants
US5683684A (en) * 1991-04-03 1997-11-04 L'oreal Use of sphingolipids in the preparation of a cosmetic or dermopharmaceutical composition protecting the skin and hair against the harmful effects of atmospheric pollution
EP0535446A1 (fr) * 1991-09-30 1993-04-07 BONISCONTRO E GAZZONE S.r.l. Compositions pharmaceutiques à usage topique contenant un agent de chelation, un tocophérol et un agent antimicrobien
WO1994026263A2 (fr) * 1993-05-06 1994-11-24 The Wellcome Foundation Limited Utilisation d'un complexe metallique de transition pour le traitement du choc septique
WO1996030012A1 (fr) * 1995-03-24 1996-10-03 Defeudis Francis V Procedes de traitement de conditions associees a des excedents d'oxyde d'azote
JPH08333260A (ja) * 1995-06-06 1996-12-17 Kaminomoto Honpo:Kk 皮膚外用剤
WO1997015280A1 (fr) * 1995-10-26 1997-05-01 L'oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
JPH10120557A (ja) * 1996-10-16 1998-05-12 Sekisui Chem Co Ltd 創傷治療物質
JPH10279485A (ja) * 1997-04-01 1998-10-20 Nisshin Oil Mills Ltd:The 組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199709, Derwent World Patents Index; Class B05, AN 1997-095410, XP002198007 *
DATABASE WPI Section Ch Week 199829, Derwent World Patents Index; Class B05, AN 1998-328378, XP002198009 *
DATABASE WPI Section Ch Week 199901, Derwent World Patents Index; Class B02, AN 1999-005165, XP002198008 *
SAUERMANN G ET AL: "Influence of NO-Synthase Antagonists in Rosacea Patients", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 4, no. 108, 1 April 1997 (1997-04-01), pages 657, XP002075670, ISSN: 0022-202X *

Also Published As

Publication number Publication date
FR2825920B1 (fr) 2006-04-28
FR2825920A1 (fr) 2002-12-20
WO2002102345A2 (fr) 2002-12-27

Similar Documents

Publication Publication Date Title
EP2311488A3 (fr) Composition vaccinale
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
HUP0402566A3 (en) C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
WO2002022559A3 (fr) Derives des acides hexenoique et hexynoique 2-amino-2-alkyl-4 inhibiteurs de la synthase de l'oxyde nitrique
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
WO2004005472A3 (fr) Inhibiteurs de ftsz et leurs utilisations
AU2002231219A1 (en) Water soluble, randomly substituted partial n-, partial o-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof
AU2002231961A1 (en) Detectable compositions, methods of forming the same and detection techniques
MXPA03003314A (es) Compuestos de c-nitrosoanilina y sus mezclas como inhibidores de polimerizacion.
AU2003239614A1 (en) Cardiolipin compositions, methods of preparation and use
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
MXPA03002207A (es) Derivados de acido 2-amino-2-alquil-5-heptenoico y -heptinoico utiles como inhibidores de la oxido nitrico sintasa.
WO2003000186A3 (fr) Nouvelles phenylamino-pyrimidines et leur utilisation
WO2002100442A3 (fr) Utilisation de l-polynucleotides et de leurs derives
WO2002005643A3 (fr) Compositions de biocides, et procedes et systemes utilisant ces compositions
WO2002050067A3 (fr) Composes pharmaceutiques
AU2001275677A1 (en) 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants
AU2003201071A1 (en) Stable pharmaceutical compositions comprising ace inhibitor(s)
HUP0400438A3 (en) Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them
WO2002062304A3 (fr) Agents cosmetiques et/ou pharmaceutiques
AU2002248432A1 (en) Oxazole derivatives, their preparation and their use as cytokine inhibitors
AU2002361337A1 (en) Amphoteric polysaccharide, composition and use
WO2002022150A3 (fr) Medicament contenant de l'antithrombine iii activee
AU2002360117A1 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
AU2002251801A1 (en) Composition containing hedychium extract and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP